Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H26FNO4 |
| Molecular Weight | 339.4017 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(F)C=C1C[C@@](O)(C2CCOCC2)[C@@H]3CNCCO3
InChI
InChIKey=CPBHSHYQQLFAPW-ZWKOTPCHSA-N
InChI=1S/C18H26FNO4/c1-22-16-3-2-15(19)10-13(16)11-18(21,14-4-7-23-8-5-14)17-12-20-6-9-24-17/h2-3,10,14,17,20-21H,4-9,11-12H2,1H3/t17-,18+/m0/s1
| Molecular Formula | C18H26FNO4 |
| Molecular Weight | 339.4017 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Edivoxetine (LY-2216684) is a highly selective norepinephrine reuptake inhibitor. It is under development as adjunctive or monotherapy of disorders believed to be associated with alterations in norepinephrine transmission within the central nervous system. Currently, edivoxetine is being studied in the treatment of attention-deficit hyperactivity disorder. Edivoxetine development in the treatment of major depressive disorder has been discontinued.
Originator
Approval Year
Sample Use Guides
Open-label study of edivoxetine once daily dosing (0.1-0.3 mg/kg) as treatment for ADHD in children (6-11 years) and adolescents (12-17 years) to assess safety for up to 5 years.
The efficacy, tolerability, and safety of edivoxetine were studied in adult patients with major depressive disorder (MDD). This randomized, double-blind study compared flexible-dose edivoxetine 6-18 mg once daily with placebo for 10 weeks acute therapy followed by 1 year edivoxetine treatment
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 08:45:30 GMT 2025
by
admin
on
Wed Apr 02 08:45:30 GMT 2025
|
| Record UNII |
3W9N3F4JOO
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB09184
Created by
admin on Wed Apr 02 08:45:30 GMT 2025 , Edited by admin on Wed Apr 02 08:45:30 GMT 2025
|
PRIMARY | |||
|
1194508-25-2
Created by
admin on Wed Apr 02 08:45:30 GMT 2025 , Edited by admin on Wed Apr 02 08:45:30 GMT 2025
|
PRIMARY | |||
|
9344
Created by
admin on Wed Apr 02 08:45:30 GMT 2025 , Edited by admin on Wed Apr 02 08:45:30 GMT 2025
|
PRIMARY | |||
|
Edivoxetine
Created by
admin on Wed Apr 02 08:45:30 GMT 2025 , Edited by admin on Wed Apr 02 08:45:30 GMT 2025
|
PRIMARY | |||
|
UU-108
Created by
admin on Wed Apr 02 08:45:30 GMT 2025 , Edited by admin on Wed Apr 02 08:45:30 GMT 2025
|
PRIMARY | |||
|
C166706
Created by
admin on Wed Apr 02 08:45:30 GMT 2025 , Edited by admin on Wed Apr 02 08:45:30 GMT 2025
|
PRIMARY | |||
|
11186829
Created by
admin on Wed Apr 02 08:45:30 GMT 2025 , Edited by admin on Wed Apr 02 08:45:30 GMT 2025
|
PRIMARY | |||
|
CHEMBL2103857
Created by
admin on Wed Apr 02 08:45:30 GMT 2025 , Edited by admin on Wed Apr 02 08:45:30 GMT 2025
|
PRIMARY | |||
|
300000034130
Created by
admin on Wed Apr 02 08:45:30 GMT 2025 , Edited by admin on Wed Apr 02 08:45:30 GMT 2025
|
PRIMARY | |||
|
3W9N3F4JOO
Created by
admin on Wed Apr 02 08:45:30 GMT 2025 , Edited by admin on Wed Apr 02 08:45:30 GMT 2025
|
PRIMARY | |||
|
DTXSID70152464
Created by
admin on Wed Apr 02 08:45:30 GMT 2025 , Edited by admin on Wed Apr 02 08:45:30 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
